Yongwu Shao Selected Research

Cobicistat

10/2019

Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yongwu Shao Research Topics

Disease

2	HIV Infections (HIV Infection) 11/2023 - 01/2021
2	Infections 01/2021 - 10/2010
1	Weight Gain 01/2021
1	Sexually Transmitted Diseases (Sexually Transmitted Disease) 01/2021
1	Back Pain (Backache) 10/2019
1	Nasopharyngitis 10/2019
1	Bronchitis 10/2019
1	Vitamin D Deficiency 10/2019
1	Arthralgia (Joint Pain) 10/2019
1	Type 2 Diabetes Mellitus (MODY) 01/2015
1	Chronic Hepatitis C 01/2011
1	Fibrosis (Cirrhosis) 01/2011

Drug/Important Bio-Agent (IBA)

3	Emtricitabine (Emtriva)FDA Link 11/2023 - 10/2019
3	Tenofovir (Viread)FDA Link 11/2023 - 10/2019
2	tenofovir alafenamideIBA 01/2021 - 10/2019
2	InterferonsIBA 01/2011 - 10/2010
1	RacivirIBA 11/2023
1	TabletsIBA 01/2021
1	CobicistatIBA 10/2019
1	elvitegravirIBA 10/2019
1	Metformin (Glucophage)FDA LinkGeneric 01/2015
1	Ranolazine FDA Link 01/2015
1	Ribavirin (Virazole)FDA LinkGeneric 01/2011
1	RNA (Ribonucleic Acid)IBA 01/2011